- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about LGND
Recent news which mentions LGND
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
From Benzinga
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Tickers
LGND
From Benzinga
Why Are Novan Shares Nosediving Today?
July 17, 2023
From Benzinga
From InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
May 16, 2023
From Benzinga
Earnings Scheduled For February 22, 2023
February 22, 2023
From Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
From Benzinga
From Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
December 23, 2022
Tickers
LGND
From Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
December 23, 2022
From Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
December 16, 2022
From Benzinga
Best stock picks for 2023: Here are Wall Street analysts’ most heavily favored choices
December 13, 2022
From MarketWatch
These small-cap stocks might make you the most money in 2023, based on two important data points
December 07, 2022
From MarketWatch
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
From Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
From Benzinga
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know
July 05, 2022
Tickers
LGND
From Benzinga
ASCO 2022: Surprising News in Cancer Research
June 10, 2022
From Motley Fool
10 Biggest Price Target Changes For Monday
May 16, 2022
From Benzinga
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 23, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.